CA3055562A1 - Combination therapy with glutaminase inhibitors - Google Patents

Combination therapy with glutaminase inhibitors Download PDF

Info

Publication number
CA3055562A1
CA3055562A1 CA3055562A CA3055562A CA3055562A1 CA 3055562 A1 CA3055562 A1 CA 3055562A1 CA 3055562 A CA3055562 A CA 3055562A CA 3055562 A CA3055562 A CA 3055562A CA 3055562 A1 CA3055562 A1 CA 3055562A1
Authority
CA
Canada
Prior art keywords
cancer
tumor
arylalkyl
cell
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3055562A
Other languages
English (en)
French (fr)
Inventor
Susan D. Bromley
Francesco Parlati
Matthew I. Gross
Keith ORFORD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calithera Biosciences Inc
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CA3055562A1 publication Critical patent/CA3055562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3055562A 2017-03-10 2018-03-09 Combination therapy with glutaminase inhibitors Abandoned CA3055562A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469633P 2017-03-10 2017-03-10
US62/469,633 2017-03-10
US201862621416P 2018-01-24 2018-01-24
US62/621,416 2018-01-24
PCT/US2018/021689 WO2018165516A1 (en) 2017-03-10 2018-03-09 Combination therapy with glutaminase inhibitors

Publications (1)

Publication Number Publication Date
CA3055562A1 true CA3055562A1 (en) 2018-09-13

Family

ID=63447983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3055562A Abandoned CA3055562A1 (en) 2017-03-10 2018-03-09 Combination therapy with glutaminase inhibitors

Country Status (8)

Country Link
US (1) US20200038398A1 (enExample)
EP (1) EP3592354A4 (enExample)
JP (1) JP2020510032A (enExample)
KR (1) KR20190125432A (enExample)
CN (1) CN110730664A (enExample)
AU (1) AU2018231058A1 (enExample)
CA (1) CA3055562A1 (enExample)
WO (1) WO2018165516A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013344560B2 (en) 2012-11-16 2017-09-14 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
EA202091841A1 (ru) * 2018-02-12 2020-10-28 Астразенека Аб Осимертиниб для применения для лечения немелкоклеточного рака легкого
US20220054606A1 (en) * 2018-12-19 2022-02-24 University Of Maryland, Baltimore Asparaginase-induced glutamine depletion combined with bcl-2 inhibition for treatment of hematologic and solid cancers
US20220313700A1 (en) * 2019-02-26 2022-10-06 Cell Response, Inc. Methods for treating map3k8 positive cancers
CN111166886B (zh) * 2019-06-26 2022-03-22 百济神州(北京)生物科技有限公司 谷氨酰胺酶抑制剂和Dyrk1B抑制剂用于治疗实体瘤的用途
CN110804643B (zh) * 2019-10-29 2022-06-21 同济大学 一种体外评价卡介苗对中性粒细胞活性影响的方法
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
CN111514460B (zh) * 2020-05-22 2021-12-14 西安交通大学 大气压冷等离子体在抑制谷氨酰胺酶活性方面的用途及酶抑制剂
KR20220056730A (ko) * 2020-10-28 2022-05-06 의료법인 성광의료재단 Abt263을 유효성분으로 포함하는 디스크 질환 예방 및 치료용 조성물
KR20230001587A (ko) * 2021-06-28 2023-01-05 연세대학교 산학협력단 암의 예방 또는 치료용 약학 조성물
CN114107494A (zh) * 2021-09-30 2022-03-01 浙江大学 用于软骨肉瘤诊治的生物标记物及谷氨酰胺酶抑制剂在制备治疗软骨肉瘤药物中的应用
EP4536250A1 (en) * 2022-06-10 2025-04-16 Deutsches Krebsforschungszentrum Cancer treatment by arsenic trioxide combination therapy
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
CN119454681A (zh) * 2024-11-08 2025-02-18 北京润州生物科技有限公司 肾型谷氨酰胺酶抑制剂及其联合用药的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
SG11201610333VA (en) * 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
MX383034B (es) * 2015-04-06 2025-03-13 Calithera Biosciences Inc Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
WO2017021177A1 (en) * 2015-08-04 2017-02-09 Universitat De Barcelona Pharmaceutical combinations for use in the treatment of cancer

Also Published As

Publication number Publication date
EP3592354A1 (en) 2020-01-15
US20200038398A1 (en) 2020-02-06
WO2018165516A1 (en) 2018-09-13
EP3592354A4 (en) 2021-04-07
AU2018231058A1 (en) 2019-09-19
CN110730664A (zh) 2020-01-24
KR20190125432A (ko) 2019-11-06
JP2020510032A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
US9687485B2 (en) Combination therapy with glutaminase inhibitors
CA3055562A1 (en) Combination therapy with glutaminase inhibitors
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
US10278968B2 (en) Combination therapy with glutaminase inhibitors
US20150258082A1 (en) Combination therapy with glutaminase inhibitors
WO2016014890A1 (en) Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
AU2016246521A1 (en) Treatment of lung cancer with inhibitors of glutaminase
US10195197B2 (en) Combination therapy with glutaminase inhibitors
HK40020656A (en) Combination therapy with glutaminase inhibitors
HK1241274B (zh) 用谷氨酰胺酶抑制剂的组合疗法
HK40010184A (en) Combination therapy with glutaminase inhibitors
HK1241274A1 (en) Combination therapy with glutaminase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230911